Oruka Therapeutics, Inc. ORKA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $109.86M+9.2% | $100.64M-32.0% | $148.06M+2.3% | $144.76M+3.9% | $139.35M+11.8% | ||
| $23.54M+9.9% | $21.41M-22.7% | $27.68M+5.2% | $26.32M+6.1% | $24.8M+16.4% | ||
| $133.4M+9.3% | $122.05M-30.6% | $175.74M+2.7% | $171.09M+4.2% | $164.15M+12.5% | ||
| -$133.4M-9.3% | -$122.05M+30.6% | -$175.74M-2.7% | -$171.09M-4.2% | -$164.15M-12.5% | ||
| $17.15M+3.2% | $16.62M+2.8% | $16.17M+22.8% | $13.17M+53.8% | $8.56M+101% | ||
| -$116.25M-10.3% | -$105.43M+33.9% | -$159.57M-1.0% | -$157.92M-1.5% | -$155.59M-9.8% | ||
| -$133.29M-9.3% | -$121.97M+30.6% | -$175.66M-2.7% | -$171.01M-4.2% | -$164.09M-12.5% | ||
| -$133.4M-9.3% | -$122.05M+30.6% | -$175.74M-2.7% | -$171.09M-4.2% | -$164.15M-12.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Oruka Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Oruka Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.